- Rockley set to ship initial commercial units of its Bioptx™
biomarker sensing wristbands to medtech customers in Q4 2022
- Rockley supply chain preparing to support volume production of
biosensing wristbands and other products in 2023
- Unique biosensing wristband features flexible design that
supports multiple applications and uses
Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a
global leader in photonics-based health monitoring and
communications solutions, today announced that it has signed a
supply agreement outlining the customer’s initial purchase
commitment for 2023 and received the first commercial purchase
order for its non-invasive biomarker sensing wristbands from a
global healthcare technology provider. The Bioptx™ Baseline devices
included in this order will employ Rockley’s biosensing technology,
a complete end-to-end solution that enables the non-invasive,
continuous, and near-real-time monitoring of multiple biomarkers.
The initial units are expected to ship in Q4 2022, which could put
Rockley’s ground-breaking biosensing technology on the wrists of
end-users by the end of 2022.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220809005571/en/
Hero shot showing bottom of device and
strap (Photo: Business Wire)
The Rockley Bioptx band represents a new class of wearable
biosensing devices, with enhanced health monitoring capabilities
and a flexible design that’s appropriate for a multitude of
applications and uses, such as professional healthcare or general
health and wellness. The form and function of the device allow it
to be worn on the wrist or other locations on the body, depending
on the use case and physical requirements. In addition to a
versatile form factor, the Bioptx band features a flexible hardware
design that will support a range of software stacks that can be
customized to address the specific needs of various customers. The
software can be further adjusted to optimize battery life for
extended use or maximize performance for intensive duty cycles.
Dr. Andrew Rickman, chairman and chief executive officer of
Rockley, said, “This is a pivotal moment for Rockley as our medtech
customers begin to deploy wearable, non-invasive biosensing
solutions that could help improve patient treatment. To support the
demand, we have established the manufacturing partnerships to
provide high-volume production, which is planned for 2023. This
initial order, along with the commitment for future orders,
represents a significant step toward expanding our ‘Powered by
Rockley’ presence in the medtech market — and brings us closer to
our goal of empowering people with timely insights and fostering a
more personalized approach to managing health and well-being.”
Rockley's photonics-based biomarker sensing platform
miniaturizes the capabilities of lab-based spectrometers onto a
single wrist-worn device, enabling a new class of wearable health
monitoring solutions. Rockley has conducted several human studies
designed to validate the performance of its solution. The results
of these ongoing studies continue to help enhance functionality and
will support the delivery of non-invasive biosensing products to
customers. Rockley expects to work with its partners and customers
toward receiving clearance of Rockley-powered wearable devices from
the U.S. Food and Drug Administration (FDA) and other regulatory
agencies.
More information about Rockley’s digital health monitoring
solution is available here:
https://rockleyphotonics.com/healthcare-sensing/.
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “anticipate,” “believe,” “can,”
“capability,” “continue,” “could,” “develop,” “enable,” “enhance”,
“estimate,” “eventual,” “expand, “expect,” “focus,” “forward,”
“future,” “goal,” “ground-breaking” “intend,” “may,” “might,”
“opportunity,” “outlook,” “plan,” “possible,” “position,”
“potential,” “predict,” “project,” “revolutionize,” “seem,”
“should,” “trend,” “vision,” “will,” “would” or other terms that
predict or indicate future events, trends, or expectations, and
similar expressions or the negative of such expressions may
identify forward-looking statements, but the absence of these words
or terms does not mean that a statement is not forward-looking.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the following: (a) the
potential of Rockley’s sensing platform to provide a complete
end-to-end solution that enables the non-invasive, continuous, and
near-real-time monitoring of multiple biomarkers; (b) the timing of
shipment and use of our products; (c) our belief that our products
are a new class of wearable biosensing devices; (d) the
applications and uses of our products, including the potential use
for professional healthcare; (e) our ability to customize our
products to address the specific needs of various customers; (f)
the battery life of our products; (g) the ability of our products
to improve patient treatment: (h) the timing of, and ability of our
manufacturing partners to provide, high volume production; (i) our
ability to empower people with timely insights and foster a more
personalized approach to managing health and well-being; (j) our
platform’s ability to miniaturize the capabilities of lab-based
spectrometers onto a single wrist-worn device; (k) our ability to
obtain FDA approval for our products; (l) our belief that photonics
will eventually become as pervasive as micro-electronics; and (m)
our potential to support hyper-scale manufacturing, address a
multitude of high-volume markets, and deliver the complex optical
systems required to bring transformational products to market.
Forward-looking statements are subject to several risks,
assumptions, and uncertainties (many of which are beyond Rockley’s
control) that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks, assumptions, and uncertainties include,
but are not limited to, the factors described under the heading
“Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2021 and in other documents we file with the
Securities and Exchange Commission. If any of these risks or
uncertainties materialize, or should any of these assumptions prove
incorrect, actual results may differ materially from those
discussed in or implied by these forward-looking statements. There
can be no assurance that future developments affecting Rockley will
be those that have been anticipated. Given these risks and
uncertainties, you should not place undue reliance on these
forward-looking statements. These forward-looking statements speak
only as of the date hereof and Rockley does not intend to update or
revise any forward-looking statements, whether because of new
information, future events, or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220809005571/en/
Media Debra Raine Rainemakers Telephone: +1 415-349-7432 Email:
rockleyphotonics@rainemakers.com
Investors Gwyn Lauber Rockley Photonics Telephone: +1
626-995-0001 Email: investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Aug 2023 to Aug 2024